Despite softer than expected Q4 results and uncertainty around its China business, Herbalife Nutrition's fiscal 2019 guidance will likely end up being conservative owing to positive momentum in sales in most regions excluding China, Jefferies analyst Akshay Jagdale tells investors in a research note. The analyst continues to believe Herbalife can sustainably grow sales at least inline with its total addressable market growth rate of 6%, expand margins, and drive incremental earnings upside via accretive free cash flow usage. He keeps a Buy rating on the shares with a $65 price target.